Catalyst Pharmaceuticals Inc. (CPRX)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.68 per share a year ago.
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Catalyst (CPRX) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
The move marks Italy's Angelini Pharma's entry into the U.S. market.
